爆竹声中一岁除。 得益于全球肿瘤学者的不懈努力和开拓创新，2024 年肿瘤诊疗取得了突破性的发展， 乳腺癌 领域亦是如此。多款创新药研发、多个新靶点探索，开创了乳腺癌诊疗的崭新局面。为回顾 2024 ...

The FDA has granted fast track designation to emiltatug ledadotin for advanced or metastatic breast cancer treatment, as ...

Mersana shares Phase 1 data on Emi-Le for TNBC and details FDA's Fast Track status for XMT-1660 in advanced HER2-low breast ...

Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...

REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker ...

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of ...

VIR-5818 is under clinical development by Vir Biotechnology and currently in Phase II for Metastatic Colorectal Cancer.

Vir Biotechnology (VIR) is presenting initial Phase 1 data from two of its dual-masked T-cell engagers: VIR-5818, targeting a variety of ...